One recent clinical trial showed that ertugliflozin improved the declining eGFR in patients with DKD, especially those without albuminuria, suggesting that SGLT2 inhibitors may be more suitable for patients with nonalbuminuric DKD [261]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.